2021년 November 30일

미국 이차 부갑상선 기능 항진증 치료 시장 동향 기술, 개발 계획 및 미래 성장 예측 2027

The increasing launch of effective drugs is a key factor driving the “US Secondary Hyperparathyroidism Treatment Market” Size says Fortune Business Insights in a report, titled “Secondary Hyperparathyroidism Treatment (SHPT) Market” ,Size, Share & Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital & Retail Pharmacies, Online Channels, and Others) and Region Forecast, 2019-2026.” The secondary hyperparathyroidism treatment (SHPT) market was valued at USD 4.34 Billion in 2018 and is expected to reach USD 7.06 Billion by 2026, exhibiting a CAGR of 9.0%. As per the report the secondary hyperparathyroidism treatment market on the basis of drug class is segmented into calcimimetics, vitamin d analogues, and phosphate binders.

Request a Sample Copy of the Research Report: 

www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Rising Prevalence Of Chronic Kidney Disease Will Stimulate Growth 

The increasing prevalence of chronic kidney disease among geriatric population as well as general population will enable the growth of the secondary hyperparathyroidism treatment market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), around 15% of U.S adults, which, is, 37 million people are estimated to have chronic kidney disease. Additionally, CKD is found more common in people aged 65 years or older than in people aged 45-64 years. The rising cases of renal disease and increasing patient pool will have a significant impact on the market. The increasing cost burden for the treatment of secondary hyperparathyroidism will further encourage growth of the market. In addition, the launch of generic form of Cinacalcet hydrochloride tablets will bode well for the secondary hyperparathyroidism treatment market. For instance, Cipla Inc. and its subsidiary Cipla USA Inc. announced the launch of a generic form of Cinacalcet hydrochloride tablets in USA. Moreover, Amgen Inc. announced the USFDA approval of Parsabiv for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD). The approval for Parsabiv will also aid the growth of the market during the forecast period.

Leading Players operating in the U.S Secondary Hyperparathyroidism Treatment Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Genzyme Corporation (Sanofi)
  • AbbVie Inc.
  • Cipla Inc.
  • Reddy’s Laboratories Ltd.
  • OPKO Health, Inc.
  • Other Prominent Players

Emerging Guidelines By Government Authorities Will Boost Growth

The increasing government initiatives for improvising secondary hyperparathyroidism management will create growth opportunities for the secondary hyperparathyroidism treatment market. The aim of SHPT treatment is to manage the biochemical markers of bone and mineral metabolism, which are directly linked to cardiovascular events and bone fractures by extensive epidemiologic evidence. International & national organizations in the U.S. and working groups such as the National Kidney Foundation have published various clinical guidance documents to encourage best practices in managing SHPT. Furthermore, increasing awareness about SHPT in physicians, as well as clinical specialists, have improved the treatment regimen for its management. The improvement in earlier identification and assessment of SHPT for mineral metabolism in CKD & ESRD will have a positive impact on secondary hyperparathyroidism treatment market growth. The reduction in associated complications for the management of SHPT is expected to accelerate growth of the market during the forecast period.

Quick Buy – U.S Secondary Hyperparathyroidism Treatment Market Research Report:

www.fortunebusinessinsights.com/checkout-page/101664

Reasons to Purchase this Report:

  • Comprehensive analysis of the U.S Secondary Hyperparathyroidism Treatment Market growth drivers, obstacles, opportunities, and other related challenges.
  • Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
  • Identifies market restraints and boosters.
  • Identifies all the possible segments present in the market to aid organizations in strategic business planning.

Table of Content:

1 Secondary Hyperparathyroidism Treatment (SHPT) Market Overview

1.1 Secondary Hyperparathyroidism Treatment (SHPT) Product Overview

1.2 Secondary Hyperparathyroidism Treatment (SHPT) Market Segment by Type

1.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size by Type (2015-2027)

1.3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Overview by Type (2015-2027)

1.3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Historic Market Size Review by Type (2015-2021)

1.3.2.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share Breakdown by Type (2015-2027)

1.3.2.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Share Breakdown by Type (2015-2027)

1.3.2.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Average Selling Price (ASP) by Type (2015-2027)

1.3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Forecast by Type (2021-2027)

1.3.3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share Breakdown by Application (2021-2027)

1.3.3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share Breakdown by Application (2021-2027)

1.3.3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Average Selling Price (ASP) by Application (2021-2027)

1.4 Key Regions Market Size Segment by Type (2015-2021)

1.4.1 North America Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.2 Europe Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.3 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.4 Latin America Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

1.4.5 Middle East and Africa Secondary Hyperparathyroidism Treatment (SHPT) Sales Breakdown by Type (2015-2027)

2 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Competition by Company

2.1 Global Top Players by Secondary Hyperparathyroidism Treatment (SHPT) Sales (2015-2021)

2.2 Global Top Players by Secondary Hyperparathyroidism Treatment (SHPT) Revenue (2015-2021)

2.3 Global Top Players Secondary Hyperparathyroidism Treatment (SHPT) Average Selling Price (ASP) (2015-2021)

2.4 Global Top Company Secondary Hyperparathyroidism Treatment (SHPT) Manufacturing Base Distribution, Sales Area, Product Type

2.5 Secondary Hyperparathyroidism Treatment (SHPT) Market Competitive Situation and Trends

2.5.1 Secondary Hyperparathyroidism Treatment (SHPT) Market Growth Rate (2015-2021)

2.5.2 Global 5 and 10 Largest Company by Secondary Hyperparathyroidism Treatment (SHPT) Sales and Revenue in 2019

2.6 Global Top Company by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Hyperparathyroidism Treatment (SHPT) as of 2019)

2.7 Date of Key Company Enter into Secondary Hyperparathyroidism Treatment (SHPT) Market

2.8 Key Company Secondary Hyperparathyroidism Treatment (SHPT) Product Offered

2.9 Mergers and Acquisitions, Expansion

3 Global Secondary Hyperparathyroidism Treatment (SHPT) Status and Outlook by Region (2015-2027)

3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size and CAGR by Region: 2015 VS 2021 VS 2027

3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Market Share by Region (2015-2021)

3.2.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Region (2015-2021)

3.2.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Region (2015-2021)

3.2.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales, Revenue, Price and Gross Margin (2015-2021)

3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Market Size Market Share by Region (2021-2027)

3.3.1 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales Market Share by Region (2021-2027)

3.3.2 Global Secondary Hyperparathyroidism Treatment (SHPT) Revenue Market Share by Region (2021-2027)

3.3.3 Global Secondary Hyperparathyroidism Treatment (SHPT) Sales, Revenue, Price and Gross Margin (2021-2027)

3.4 North America Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.4.1 North America Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.4.2 North America Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

3.5 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.5.1 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.5.2 Asia-Pacific Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

3.6 Europe Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.6.1 Europe Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.6.2 Europe Secondary Hyperparathyroidism Treatment (SHPT) Sales By Growth (2015-2027)

3.7 Latin America Secondary Hyperparathyroidism Treatment (SHPT) Market Size By Growth (2015-2027)

3.7.1 Latin America Secondary Hyperparathyroidism Treatment (SHPT) Revenue By Growth (2015-2027)

3.7.2 라틴 아메리카 이차 부갑상선 기능 항진증 치료 (SHPT) 판매 성장 (2015-2027)

3.8 성장(2015-2027)별 중동 및 아프리카 이차 부갑상선 기능 항진증 치료(SHPT) 시장 규모

3.8.1 성장(2015-2027)별 중동 및 아프리카 이차 부갑상선 기능 항진증 치료(SHPT) 수익

3.8.2 성장(2015-2027)별 중동 및 아프리카 이차 부갑상선 기능 항진증 치료(SHPT) 판매

4 적용별 글로벌 이차성 부갑상선기능항진증 치료(SHPT)

4.1 응용 프로그램별 이차 부갑상선 기능 항진증 치료(SHPT) 세그먼트

4.1.1 주거

4.1.2 상업

4.2 애플리케이션별 글로벌 이차성 부갑상선 기능 항진증 치료(SHPT) 판매: 2015년 VS 2021년 VS 2027년

4.3 글로벌 이차성 부갑상선 기능 항진증 치료(SHPT) 과거 판매 애플리케이션(2015-2021년)

4.4 글로벌 이차성 부갑상선 기능 항진증 치료 (SHPT) 응용 프로그램 별 예상 판매 (2021-2027)

4.5 응용 프로그램별 주요 지역 이차 부갑상선 기능 항진증 치료 (SHPT) 시장 규모

4.5.1 북미 이차 부갑상선 기능 항진증 치료 (SHPT) 응용 프로그램

4.5.2 유럽 이차성 부갑상선기능항진증 치료(SHPT) 적용

4.5.3 적용별 아시아 태평양 이차성 부갑상선 기능 항진증 치료(SHPT)

4.5.4 라틴 아메리카 이차 부갑상선 기능 항진증 치료 (SHPT) 응용 프로그램

4.5.5 중동 및 아프리카 이차 부갑상선 기능 항진증 치료 (SHPT) 응용 프로그램

회사 소개:

Fortune Business Insights™는 정확한 데이터와 혁신적인 기업 분석을 제공하여 모든 규모의 조직이 적절한 결정을 내릴 수 있도록 지원합니다. 우리는 고객을 위한 새로운 솔루션을 맞춤화하여 고객이 비즈니스 고유의 다양한 문제를 해결할 수 있도록 지원합니다. 우리의 목표는 그들이 운영하고 있는 시장에 대한 세부적인 개요를 제공하여 전체적인 시장 인텔리전스를 제공하는 것입니다.

문의하기:

Fortune Business Insights™ Pvt. 주식회사

308, 최고 본부,

설문 조사 번호 36, Baner,

푸네-방갈로르 고속도로,

푸네 – 411045, 마하라슈트라, 인도.

핸드폰:

미국:+1 424 253 0390

영국: +44 2071 939123

APAC: +91 744 740 1245

이메일: [email protected]